{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+of+Care+%28SOC%29&page=9",
    "query": {
      "intervention": "Standard of Care (SOC)",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 1108,
    "total_pages": 111,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+of+Care+%28SOC%29&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+of+Care+%28SOC%29&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T18:47:31.183Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01681030",
      "title": "The Fibrin Pad Cardiovascular Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cardiovascular Disease"
      ],
      "interventions": [
        {
          "name": "EVARREST™",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Topical hemostat",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard of Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Ethicon, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2012-08-01",
      "completion_date": "2013-09-03",
      "has_results": true,
      "last_update_posted_date": "2018-06-12",
      "last_synced_at": "2026-10-17T18:47:31.183Z",
      "location_count": 6,
      "location_summary": "Indianapolis, Indiana • Kansas City, Missouri • Camden, New Jersey + 2 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Camden",
          "state": "New Jersey"
        },
        {
          "city": "Paterson",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01681030"
    },
    {
      "nct_id": "NCT03575351",
      "title": "A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin"
      ],
      "interventions": [
        {
          "name": "Standard of Care",
          "type": "DRUG"
        },
        {
          "name": "JCAR017",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "DRUG",
        "GENETIC"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 184,
      "start_date": "2018-10-23",
      "completion_date": "2023-10-23",
      "has_results": true,
      "last_update_posted_date": "2025-08-03",
      "last_synced_at": "2026-10-17T18:47:31.183Z",
      "location_count": 28,
      "location_summary": "Scottsdale, Arizona • San Francisco, California • Aurora, Colorado + 22 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03575351"
    },
    {
      "nct_id": "NCT05028101",
      "title": "The Impact of Functional Medicine On Wound Healing From Delayed Autologous Breast Reconstruction",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Reconstruction"
      ],
      "interventions": [
        {
          "name": "Delayed autologous breast reconstruction",
          "type": "PROCEDURE"
        },
        {
          "name": "Perioperative Functional Medicine (FM) Care",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BEHAVIORAL"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 7,
      "start_date": "2023-02-20",
      "completion_date": "2024-06-06",
      "has_results": false,
      "last_update_posted_date": "2024-06-21",
      "last_synced_at": "2026-10-17T18:47:31.183Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05028101"
    },
    {
      "nct_id": "NCT05413395",
      "title": "Assessment of the Effects on the Skin Microbiome of Amending an Over-the-counter Eczema Product With Activated Oil (AO)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Eczema"
      ],
      "interventions": [
        {
          "name": "topical colloidal oatmeal formulation with a modified plant oil",
          "type": "OTHER"
        },
        {
          "name": "topical colloidal oatmeal formulation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "GlycosBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2022-06-17",
      "completion_date": "2024-03-01",
      "has_results": false,
      "last_update_posted_date": "2022-07-05",
      "last_synced_at": "2026-10-17T18:47:31.183Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05413395"
    },
    {
      "nct_id": "NCT04948554",
      "title": "A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Systemic Sclerosis With and Without Interstitial Lung Disease"
      ],
      "interventions": [
        {
          "name": "MK-2225",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2023-03-10",
      "completion_date": "2023-10-18",
      "has_results": false,
      "last_update_posted_date": "2023-11-24",
      "last_synced_at": "2026-10-17T18:47:31.183Z",
      "location_count": 11,
      "location_summary": "La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 8 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04948554"
    },
    {
      "nct_id": "NCT05541822",
      "title": "To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Vabametkib",
          "type": "DRUG"
        },
        {
          "name": "Lazertinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abion Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 178,
      "start_date": "2023-01-17",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2025-05-22",
      "last_synced_at": "2026-10-17T18:47:31.183Z",
      "location_count": 4,
      "location_summary": "Lake City, Florida • Orange City, Florida • Detroit, Michigan + 1 more",
      "locations": [
        {
          "city": "Lake City",
          "state": "Florida"
        },
        {
          "city": "Orange City",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05541822"
    },
    {
      "nct_id": "NCT03775486",
      "title": "Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer NSCLC"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel+carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine+carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed+carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine+cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed+cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 401,
      "start_date": "2018-12-21",
      "completion_date": "2026-09-27",
      "has_results": true,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-10-17T18:47:31.183Z",
      "location_count": 9,
      "location_summary": "Bonita Springs, Florida • St. Petersburg, Florida • Tallahassee, Florida + 6 more",
      "locations": [
        {
          "city": "Bonita Springs",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Tallahassee",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03775486"
    },
    {
      "nct_id": "NCT06780670",
      "title": "Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Investigators choice of SoC",
          "type": "DRUG"
        },
        {
          "name": "AAA817",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "MALE",
        "summary": "18 Years to 100 Years · Male only"
      },
      "enrollment_count": 443,
      "start_date": "2025-02-27",
      "completion_date": "2033-07-19",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-10-17T18:47:31.183Z",
      "location_count": 35,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 30 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06780670"
    },
    {
      "nct_id": "NCT05424354",
      "title": "Acute Partial Thickness Burn Study Comparing Transforming Powder Dressing to Standard of Care Dressing",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Wounds and Injuries"
      ],
      "interventions": [
        {
          "name": "Altrazeal (R) Transforming Powder Dressing",
          "type": "DEVICE"
        },
        {
          "name": "Standard of Care burn dressing",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "ULURU Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2022-05-26",
      "completion_date": "2026-09-30",
      "has_results": false,
      "last_update_posted_date": "2025-11-19",
      "last_synced_at": "2026-10-17T18:47:31.183Z",
      "location_count": 6,
      "location_summary": "Orange, California • Washington D.C., District of Columbia • Miami, Florida + 3 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Valhalla",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05424354"
    },
    {
      "nct_id": "NCT02952586",
      "title": "Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of the Head and Neck"
      ],
      "interventions": [
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Chemoradiation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 697,
      "start_date": "2016-11-28",
      "completion_date": "2020-08-25",
      "has_results": true,
      "last_update_posted_date": "2021-09-22",
      "last_synced_at": "2026-10-17T18:47:31.183Z",
      "location_count": 139,
      "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 91 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02952586"
    }
  ]
}